Clene INC Form 4 insider transactions

Mark Mortenson, Chief Science Officer of Clene Inc., reports the acquisition of stock options for 25,000 shares of common stock.

Clene Inc.'s CEO, Robert Dee Etherington, reports the acquisition of 25,000 stock options at an exercise price of $5.15 per share.

Clene Inc.'s Chief Financial Officer, Morgan R Brown, was granted options to purchase 10,000 shares of common stock at an exercise price of $5.15 on August 16, 2024.

Clene Inc.'s CEO, Robert Dee Etherington, exercised stock options following a 1-for-20 reverse stock split, as reported in a Form 4 filing with the SEC.

Clene Inc.'s Chief Financial Officer, Morgan R. Brown, was granted stock options for 1,000,000 shares of common stock on June 7, 2024.

Director Vallerie McLaughlin received stock options for 37,074 shares of Clene Inc. common stock on June 7, 2024.

Director Jacobovitz Shalom was granted options to purchase 50,135 shares of Clene Inc. common stock at an exercise price of $0.37 per share.

Director David J. Matlin reports acquisition of stock options in Clene Inc. on June 7, 2024.

Director Arjun Desai acquired stock options for 38,760 shares of Clene Inc. common stock on June 7, 2024.

Mark Mortenson, Chief Science Officer of Clene Inc., was granted stock options for 2,800,000 shares of common stock on June 7, 2024.

Clene Inc.'s CEO, Robert Dee Etherington, was granted stock options for a total of 3,150,000 shares on June 7, 2024.

Director Matthew Kiernan was granted stock options for 33,704 shares of Clene Inc. common stock on June 7, 2024.

Alison Mosca, a director of Clene Inc., was granted stock options for 51,399 shares of common stock on June 7, 2024.

Director Reed N. Wilcox reports acquisition of stock options in Clene Inc.

Director Jonathon Gay reports the acquisition of stock options in Clene Inc.

Director Shalom Jacobovitz reports the acquisition of 30,000 stock options in Clene Inc. on May 29, 2024.

Director Vallerie McLaughlin received stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

Director Alison Mosca reports acquisition of 30,000 stock options in Clene Inc.

Director Jonathon Gay acquired stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

Director David J. Matlin reports acquisition of stock options in Clene Inc.

Director Arjun Desai acquired stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

Director Reed N. Wilcox acquired 30,000 stock options in Clene Inc. on May 29, 2024, at an exercise price of $0.37 per share.

Director Matthew Kiernan acquired stock options for 30,000 shares of Clene Inc. common stock on May 29, 2024.

General Resonance LLC, a 10% owner of Clene Inc., has sold 26,000 shares of common stock over two days in late April and early May.

General Resonance LLC, a 10% owner of Clene Inc., sold 10,000 shares of common stock at a price of $0.3278 per share on April 24, 2024.

General Resonance LLC, a 10% owner of Clene Inc., disposed of 22,500 shares of common stock in a series of transactions on April 9, 2024.

Director Matthew Kiernan was granted stock options for 29,481 shares of Clene Inc. common stock on March 11, 2024.

Director David J. Matlin acquired stock options for 57,488 shares of Clene Inc. common stock on March 11, 2024.

Director Vallerie McLaughlin received stock options for 32,429 shares of Clene Inc. common stock on March 11, 2024.

Alison Mosca, a director of Clene Inc., was granted stock options for 44,959 shares of common stock on March 11, 2024.